Memphasys LtdASX: MEM

Pivotal Felix Study Receives First Scientific Presentation

Aug 9, 2026 at 7:28 PM EDT · Issued by Memphasys Ltd via ASX

Filed with ASX · Aug 9, 2026 at 7:28 PM EDT

On 6ix: 6ix.com/news/pivotal-felix-study-receives-first-scientific-presentation

Memphasys Limited Level 1, 34-36 Richmond Road Homebush West, NSW 2140 Contact Details P +612 8415 7300 E info@memphasys.com W memphasys.com ABN 33 120 047 556 ASX Release ASX Code: MEM 10 August 2026 PIVOTAL FELIX ™ STUDY RECEIVES FIRST SCIENTIFIC ...

View Attachment

6ix hasn’t read this filing yet.

Memphasys Ltd on 6ix

Story so far

ITL Orders 1000 Felix Cartridges Across MENA MarketsMay 26, 2026
Memphasys Secures TGA Approval for Felix SystemFeb 9, 2026
Regulatory Submissions Lodged for FelixFeb 3, 2026

Earlier from Memphasys

European Commercial Roll-out continues with Poland AgreementAug 4
Exclusive Thailand Commercialisation Agreement SecuredJun 30
UK Market Entry & Acceleration of Commercial ExpansionJun 24
Successful $1.2M Placement and Convertible Note ExtendedJun 17
Memphasys Executes Supply Agreement with Monash IVF GroupJun 15

Later from Memphasys

Felix Registration Achieved in Vietnam and Cartridge OrderAug 19
Results of General MeetingAug 21
Felix Early Thai FDA Approval, Commercial Launch AcceleratesAug 27
Appendix 4E and 2026 Annual ReportAug 31
Appendix 4G and Corporate Governance StatementAug 31

All Memphasys news releases

Follow Memphasys into a list and get an email when it puts out news.

Follow Memphasys